MyFinsight
Home
Blog
About
Proceeds from maturity of
marketable securities
$47,100K
(-28.67%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$1,912K
(22.72%↑ Y/Y)
Net cash provided by
(used in) investing...
$9,018K
(106.69%↑ Y/Y)
Net cash provided by
financing activities
$1,912K
(-0.83%↓ Y/Y)
Canceled cashflow
$38,082K
Net increase in
cash, cash...
-$45,655K
(-72.21%↓ Y/Y)
Canceled cashflow
$10,930K
Stock-based compensation
expense
$10,802K
(-24.73%↓ Y/Y)
Accounts payable,
accrued liabilities and...
$2,598K
(-65.39%↓ Y/Y)
Reduction in the carrying
amount of right of use...
$680K
(-43.85%↓ Y/Y)
Depreciation
$458K
(-50.38%↓ Y/Y)
Purchases of marketable
securities
$36,106K
(-82.00%↓ Y/Y)
Purchases of property and
equipment
$1,976K
(545.75%↑ Y/Y)
Net cash (used in)
provided by operating...
-$56,585K
(-153.18%↓ Y/Y)
Canceled cashflow
$14,538K
Net (loss) income
-$61,618K
(-168.93%↓ Y/Y)
Prepaid expenses and
other current assets
$3,913K
(-38.91%↓ Y/Y)
Accounts receivable
$2,729K
Deferred revenue
-$2,494K
(-308.18%↓ Y/Y)
Amortization and accretion of
marketable securities
-$369K
(-1218.18%↓ Y/Y)
Back
Back
Cash Flow
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)
source: myfinsight.com